Procept Biorobotics CORP (PRCT) Institutional Ownership & 13F Filings (Q2 2026)

PRCT ranks #2441 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

257 institutions disclose a position in PRCT, but none treat it as a major bet — even Davern Capital Partners, LP, its most concentrated holder, allocates just 1.8% of its own portfolio to it.

Versant Capital Management, Inc has added to its PRCT position for two straight quarters, increasing it by $34.3K to reach $37.0K today.

Chicago Capital, LLC has trimmed its PRCT position for two straight quarters, cutting it by $45.0M while still holding $9.0M.

PRCT is down 3.2% today, but institutions show net buying of $114.6M this quarter — a divergence between today's price move and the underlying institutional flow.

PRCT reported a net loss of $109.8M over the trailing twelve months.

• Not yet profitable — net loss of $109.8M over the trailing twelve months
• Revenue grew 22.7% year over year
• Net income declined year over year, from -$84.1M to -$109.8M
• Operating cash flow was negative, using $49.0M in cash
• Current ratio of 6.85x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.39x equity — within a conventional range